SINOGRAFIN
LOE ApproachingNDAINTRAUTERINESOLUTION
Approved
Aug 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SINOGRAFIN is an intrauterine solution approved in 1958 by Bracco for diagnostic imaging purposes. The product is a legacy radiographic contrast agent administered directly into the uterine cavity. Its mechanism and specific indications are not detailed in available data but reflect its historical role in gynecological imaging.
LOE Approaching
This legacy product faces accelerating loss of exclusivity with minimal current commercial investment, signaling a declining or maintenance-focused team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SINOGRAFIN offers limited career progression due to its approaching loss of exclusivity and minimal linked job postings. Roles on this product are typically focused on portfolio maintenance, compliance, and managed decline rather than growth or innovation.
Product Manager (Legacy)Regulatory Affairs Specialist
Worked on SINOGRAFIN at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.